Progression in diagnosis and treatment of refractory/resistant cytomegalovirus infection after solid organ transplantation

doi:10.3877/cma.j.issn.1674-3903.2024.02.003

Abstract

Abstract:

With the rapid development of solid organ transplantation (SOT) in China, the number of people infected with cytomegalovirus (CMV) is increasing. The incidence rate of resistant CMV and refractory CMV infection is also increasing, leads to the mortality increase significantly, which require clinical attention. Along with improvement of the new diagnostic technologies and new drugs, the diagnosis and treatment of refractory/resistant CMV infection continue to improve. This review summarizes the new progress in the diagnosis and treatment strategies on refractory CMV infection in SOT recipients, including the definition, the diagnosis and treatment strategies. The article is aimed to provide references for prevention and treatment of refractory/drug resistant CMV infection in organ transplant recipients.

Key words: Solid organ transplantation, Cytomegalovirus, Refractory, Resistant

Chunrong Ju, Tongyi Men, Wujun Xue. Progression in diagnosis and treatment of refractory/resistant cytomegalovirus infection after solid organ transplantation[J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(02): 86-92.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhyzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3903.2024.02.003

https://zhyzzz.cma-cmc.com.cn/EN/Y2024/V18/I02/86

Figures/Tables 1

References 60

1	Kotton CN. CMV: Prevention, diagnosis and therapy[J]. Am J Transplant, 2013, 13 Suppl 3：24-40.
2	Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation[J]. JAMA, 1989, 261(24)：3607-3609.
3	巨春蓉，练巧燕，蔡宇航，等. 胸腔脏器移植受者巨细胞病毒感染情况及预后分析[J/CD]. 中华移植杂志：电子版，2021, 15(4)：193-198.
4	巨春蓉，郝建清，何建行，等. 移植受者耐药巨细胞病毒感染的诊治[J]. 中华器官移植杂志，2023, 44(3)：146-151.
5	巨春蓉，韦兵，练巧燕，等. 实体器官移植术后巨细胞病毒肺炎的防治策略—ATS巨细胞病毒肺炎的诊治指南解读[J]. 器官移植，2019, 10(1)：88-90.
6	Yong MK, Shigle TL, Kim YJ, et al. American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation[J]. Transplant Cell Ther, 2021, 27(12)：957-967.
7	Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation[J]. Transplantation, 2018, 102(6)：900-931.
8	Humar A, Siegal D, Moussa G, et al. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients[J]. J Infect Dis, 2005, 192(7)：1154-1157.
9	Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients[J]. Am J Transplant, 2007, 7(9)：2106-2113.
10	Fisher CE, Knudsen JL, Lease ED, et al. Risk factors and outcomes of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients[J]. Clin Infect Dis, 2017, 65(1)：57-63.
11	Hofmann E, Sidler D, Dahdal S, et al. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: a case series and review of the literature[J]. Transpl Infect Dis, 2021, 23(3)：e13515.
12	Van Leer Buter CC, de Voogd DWK, Blokzijl H, et al. Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands[J]. J Antimicrob Chemother, 2019, 74(8)：2370-2376.
13	Brar S, Berry R, Raval AD, et al. Outcomes among CMV-mismatched and highly sensitized kidney transplants recipients who develop neutropenia[J]. Clin Transplant, 2022, 36(4)：e14583.
14	Kotton CN, Kamar N. New insights on CMV management in solid organ transplant patients: prevention, treatment, and management of resistant/refractory disease[J]. Infect Dis Ther, 2023, 12(2)：333-342.
15	Khawaja F, Spallone A, Kotton CN, et al. Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium[J]. Clin Microbiol Infect, 2023, 29(1)：44-50.
16	Ju C, Wang X, Xu X, et al. Cytomegalovirus seroprevalence, infection, and disease in Chinese thoracic organ transplant recipients: a retrospective cohort study[J]. BMC Infect Dis, 2022, 22(1)：872.
17	Boivin G, Goyette N, Rollag H, et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir[J]. Antivir Ther, 2009, 14(5)：697-704.
18	Lurain NS, Bhorade SM, Pursell KJ, et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients[J]. J Infect Dis, 2002, 186(6)：760-768.
19	Ambrose T, Sharkey LM, Louis-Auguste J, et al. Cytomegalovirus infection and rates of antiviral resistance following intestinal and multivisceral transplantation[J]. Transplant Proc, 2016, 48(2)：492-496.
20	Limaye AP, Babu TM, Boeckh M. Progress and challenges in the prevention, diagnosis, and management of cytomegalovirus infection in transplantation[J]. Clin Microbiol Rev, 2020, 34(1)：e00043-19.
21	Linares L, Sanclemente G, Cervera C, et al. Influence of cytomegalovirus disease in outcome of solid organ transplant patients[J]. Transplant Proc, 2011, 43(6)：2145-2148.
22	Al-Badr AA, Ajarim TDS. Ganciclovir[J]. Profiles Drug Subst Excip Relat Methodol, 2018, 43：1-208.
23	El Chaer F, Shah DP, Chemaly RF. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients[J]. Blood, 2016, 128(23)：2624-2636.
24	Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus[J]. Clin Microbiol Rev, 2010, 23(4)：689-712.
25	Kleiboeker SB. Prevalence of cytomegalovirus antiviral drug resistance in transplant recipients[J]. Antiviral Res, 2023, 215：105623.
26	Jabs DA, Enger C, Forman M, et al. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group[J]. Antimicrob Agents Chemother, 1998, 42(9)：2240-2244.
27	Görzer I, Guelly C, Trajanoski S, et al. Deep sequencing reveals highly complex dynamics of human cytomegalovirus genotypes in transplant patients over time[J]. J Virol, 2010, 84(14)：7195-7203.
28	Sahoo MK, Lefterova MI, Yamamoto F, et al. Detection of cytomegalovirus drug resistance mutations by next-generation sequencing[J]. J Clin Microbiol, 2013, 51(11)：3700-3710.
29	Chou S, Ercolani RJ, Sahoo MK, et al. Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing[J]. Antimicrob Agents Chemother, 2014, 58(8)：4697-4702.
30	Chou S． Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance[J]. Antiviral Res, 2020, 176：104711.
31	Mallat SG, Tanios BY, Itani HS, et al. CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled trials[J]. Clin J Am Soc Nephrol, 2017, 12(8)：1321-1336.
32	Zafrani L, Truffaut L, Kreis H, et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study[J]. Am J Transplant, 2009, 9(8)：1816-1825.
33	Hayes M, Boge CLK, Sharova A, et al. Antiviral toxicities in pediatric solid organ transplant recipients[J]. Am J Transplant, 2022, 22(12)：3012-3020.
34	Avery RK, Arav-Boger R, Marr KA, et al. Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection[J]. Transplantation, 2016, 100(10)：e74-e80.
35	Mehta Steinke SA, Alfares M, Valsamakis A, et al. Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection[J]. Transpl Infect Dis, 2021, 23(3)：e13521.
36	Koszalka GW, Johnson NW, Good SS, et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication[J]. Antimicrob Agents Chemother, 2002, 46(8)：2373-2380.
37	Wang LH, Peck RW, Yin Y, et al. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects[J]. Antimicrob Agents Chemother, 2003, 47(4)：1334-1342.
38	Papanicolaou GA, Silveira FP, Langston AA, et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, Phase 2 study[J]. Clin Infect Dis, 2019, 68(8)：1255-1264.
39	Maertens J, Cordonnier C, Jaksch P, et al. Maribavir for preemptive treatment of cytomegalovirus reactivation[J]. N Engl J Med, 2019, 381(12)：1136-1147.
40	Avery RK, Alain S, Alexander BD, et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a Phase 3 randomized clinical trial[J]. Clin Infect Dis, 2022, 75(4)：690-701.
41	Bassel M, Romanus D, Bo T, et al. Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: data at 52 weeks post-maribavir treatment initiation[J]. Antivir Ther, 2023, 28(5)：13596535231195431.
42	Strasfeld L, Lee I, Tatarowicz W, et al. Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir[J]. J Infect Dis, 2010, 202(1)：104-108.
43	Chou S, Marousek GI. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain Ⅱ mutant[J]. J Virol, 2008, 82(1)：246-253.
44	Sassine J, Khawaja F, Shigle TL, et al. Refractory and resistant cytomegalovirus after hematopoietic cell transplant in the letermovir primary prophylaxis era[J]. Clin Infect Dis, 2021, 73(8)：1346-1354.
45	Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246[J]. Am J Transplant, 2011, 11(5)：1079-1084.
46	Phoompoung P, Ferreira VH, Tikkanen J, et al. Letermovir as salvage therapy for cytomegalovirus infection in transplant recipients[J]. Transplantation, 2020, 104(2)：404-409.
47	Turner N, Strand A, Grewal DS, et al. Use of letermovir as salvage therapy for drug-resistant cytomegalovirus retinitis[J]. Antimicrob Agents Chemother, 2019, 63(3)：e02337-18.
48	Alvarez-Cardona JJ, Whited LK, Chemaly RF. Brincidofovir: understanding its unique profile and potential role against adenovirus and other viral infections[J]. Future Microbiol, 2020, 15：389-400.
49	Marty FM, Winston DJ, Chemaly RF, et al. A randomized, double-blind, placebo-controlled Phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant, 2019, 25(2)：369-381.
50	Vial R, Zandotti C, Alain S, et al. Brincidofovir use after foscarnet crystal nephropathy in a kidney transplant recipient with multiresistant cytomegalovirus infection[J]. Case Rep Transplant, 2017：3624146.
51	Alexander BT, Hladnik LM, Augustin KM, et al. Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients[J]. Pharmacotherapy, 2010, 30(6)：554-561.
52	Wiening V, Schmidt T, Dahmen M, et al. Case report: management of a multidrug-resistant CMV-strain in a renal transplant recipient by high-dose CMV-specific immunoglobulins, modulation in immunosuppression, and induction of CMV-specific cellular immunity[J]. Front Immunol, 2020, 11：623178.
53	Pearston AP, Ingemi AI, Ripley K, et al. Successful treatment of UL97 mutation ganciclovir-resistant cytomegalovirus viremia in a renal transplant recipient with letermovir and adjunct hyperimmune cytomegalovirus immunoglobulin: a case report[J]. Transplant Proc, 2021, 53(4)：1284-1287.
54	Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis[J]. J Clin Oncol, 2009, 27(5)：770-781.
55	Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones[J]. Science, 1992, 257(5067)：238-241.
56	Ke P, Bao X, Zhou J, et al. Donor CMV-specific cytotoxic T lymphocytes successfully treated drug-resistant cytomegalovirus encephalitis after allogeneic hematopoietic stem cell transplantation[J]. Hematology, 2020, 25(1)：43-47.
57	Smith C, Beagley L, Rehan S, et al. Autologous adoptive T-cell therapy for recurrent or drug-resistant cytomegalovirus complications in solid organ transplant recipients: a single-arm open-label Phase I clinical trial[J]. Clin Infect Dis, 2019, 68(4)：632-640.
58	Holmes-Liew CL, Holmes M, Beagley L, et al. Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation[J]. Clin Transl Immunology, 2015, 4(3)：e35.
59	Miele M, Gallo A, Di Bella M, et al. Successful use of heterologous CMV-reactive T lymphocyte to treat severe refractory cytomegalovirus (CMV) infection in a liver transplanted patient: correlation of the host antiviral immune reconstitution with CMV viral load and CMV miRNome[J]. Microorganisms, 2021, 9(4)：684.
60	Macesic N, Langsford D, Nicholls K, et al. Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient[J]. Am J Transplant, 2015, 15(3)：827-832.

[1]	Qian Zhao, Yakun Li, Zhi Li. Advances in research on the clinical application of allogeneic platelet-rich plasma [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2024, 19(04): 364-367.
[2]	Peng Wang, Houan Xiao, Chiyu Jia. Research progress of different factors regulating macrophage polarization in chronic refractory wound [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(05): 454-459.
[3]	Manqing Jia, Jing Bian, Yeping Zhou. Clinical observation of low dose insulin local injection for promotion of adipose derived stem cell transplantation survival and improvement of diabetic wound healing [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(04): 312-316.
[4]	Yanyan Yin, Aixian Liu. Risk factors and prognosis of ventilator-associated pneumonia infected by multidrug-resistant organism [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2024, 18(02): 83-90.
[5]	Yongtao Wei, Songxia Wang, Aimei Su, Dongping Wang. Resistance and combination drug sensitivity test of carbapenem-resistant Pseudomonas aeruginosa [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2024, 18(01): 43-48.
[6]	Aimei Su, Yongtao Wei, Dongping Wang. Resistance and combined drug sensitivity test of carbapenem-resistant Enterobacteriaceae [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(05): 333-340.
[7]	Chunrong Ju, Qiquan Sun, Wujun Xue. Advances in the diagnosis and treatment of non-tuberculous mycobacterial disease in organ transplant recipients [J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(01): 1-6.
[8]	Haochong Hu, Yiting Liu, Jiayu Guo, Jilin Zou, Zhongbao Chen, Jiangqiao Zhou, Tao Qiu. Treatment and analysis of carbapenem-resistant Klebsiella pneumoniae infection after renal transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(04): 246-249.
[9]	Xiaolu Deng, Jie Zhao, Jian Li, Chunhui Li, Jian He, Daolin Si, Xia Wang. Post-neurosurgical intracranial infections caused by extensively drug-resistant Acinetobacter baumannii in a pediatric patient: a case report [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2024, 10(02): 205-208.
[10]	Lei Yang, Meihua Wang, jin Hu. Carbapenem-resistant Klebsiella pneumoniae infection after decompressive craniotomy for acute cerebral infarction：a case report [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2024, 10(02): 200-204.
[11]	Ying Shi, Jing Hu, Peiben Liu, Tingting Wang, Xiangrong Zuo, Quan Cao. Ceftazidime-Avibactam versus polymyxin B in the treatment of pneumonia caused by carbapenem-resistant Klebsiella pneumoniae pneumonia [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2024, 10(01): 16-24.
[12]	Daiyao Yu, Wenli Feng. Study on the effect of SAP2 and STP1 in Itraconazole resistance of Candida albicans under different states [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(03): 283-294.
[13]	Qi Li, Zhongying Huang, Ping Yuan, Zhenpeng Guan. Analysis of factors influencing nosocomial infection with multi-drug resistant bacteria in intensive care unit of a tertiary hospital [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 777-782.
[14]	Lingling Xu, Han Tian, Ping Wen, Weichun He. Rituximab for treatment of refractory minimal change disease: a case report and literature review [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 617-621.
[15]	Pingjuan Liu, Kecheng Luo, Jiayin Wu, Kang Liao, Wenwen Hu, Yili Chen. Epidemiological study on intestinal active surveillance of carbapenem-resistant Enterobacteriaceae in neurology intensive care unit [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2023, 11(04): 235-240.

Please choose a citation manager

Content to export